ICA1L has been examined as a possible drug target for SVD, AD, and other neurodegenerative diseases [32,35]; however, it is not recommended as a prioritized drug at this time due to potential side effects, including an increased risk of coronary artery disease and myocardial infarction, as well as a lower diastolic blood pressure [35]. This evidence concerns the gene ICA1L and myocardial infarction.